» Articles » PMID: 17376899

Elevated Expression Levels of Inhibitory Receptor Programmed Death 1 on Simian Immunodeficiency Virus-specific CD8 T Cells During Chronic Infection but Not After Vaccination

Overview
Journal J Virol
Date 2007 Mar 23
PMID 17376899
Citations 86
Authors
Affiliations
Soon will be listed here.
Abstract

Here, we study the temporal expression of the inhibitory receptor programmed death 1 (PD-1) on simian immunodeficiency virus (SIV) Gag-specific T cells following pathogenic SIV infection or following vaccination with a DNA/modified vaccinia virus Ankara (DNA/MVA) vaccine and simian/human immunodeficiency virus (SHIV) challenge in macaques. Following infection, the majority (>95%) of Gag-specific CD8 T cells expressed PD-1, and the level of PD-1 expression per cell increased over time. The level of PD-1 expression in lymph nodes and rectal mucosal tissue, the major sites of virus replication, was higher compared to blood. In vitro blockade of PD-1 resulted in enhanced proliferation of SIV-specific CD8 as well as CD4 T cells. In contrast, following vaccination, the majority of peak effector Gag-specific CD8 T cells expressed low levels of PD-1, and these levels decreased further as the cells differentiated into memory cells. In addition, following SHIV challenge of these vaccinated macaques, the level of PD-1 expression on Gag-specific CD8 T cells correlated positively with plasma viremia. These results demonstrate that SIV-specific CD8 T cells express PD-1 after exposure to antigen but downregulate expression under conditions of antigen clearance and enhance expression under conditions of antigen persistence. They also demonstrate that the level of PD-1 expression per cell rather than the presence or absence of expression plays an important role in regulating CD8 T-cell dysfunction in pathogenic SIV infection. In addition, they demonstrate that similar to HIV infection, the PD-1:PD-1 ligand inhibitory pathway is operational in pathogenic SIV infection, and the macaque/SIV model would be ideal to test the safety and therapeutic benefit of blocking this pathway in vivo.

Citing Articles

Immune checkpoint inhibitors in infectious disease.

King H, Lewin S Immunol Rev. 2024; 328(1):350-371.

PMID: 39248154 PMC: 11659942. DOI: 10.1111/imr.13388.


Immune restoration by TIGIT blockade is insufficient to control chronic SIV infection.

Webb G, Pessoa C, McCullen A, Hwang J, Humkey M, Thormin-Odum R J Virol. 2024; 98(6):e0027324.

PMID: 38775481 PMC: 11237531. DOI: 10.1128/jvi.00273-24.


Examining Chronic Inflammation, Immune Metabolism, and T Cell Dysfunction in HIV Infection.

Mu W, Patankar V, Kitchen S, Zhen A Viruses. 2024; 16(2).

PMID: 38399994 PMC: 10893210. DOI: 10.3390/v16020219.


Changes to the Simian Immunodeficiency Virus (SIV) Reservoir and Enhanced SIV-Specific Responses in a Rhesus Macaque Model of Functional Cure after Serial Rounds of Romidepsin Administrations.

Kleinman A, Sivanandham S, Sette P, Sivanandham R, Policicchio B, Xu C J Virol. 2022; 96(12):e0044522.

PMID: 35638831 PMC: 9215247. DOI: 10.1128/jvi.00445-22.


Lymph node CXCR5+ NK cells associate with control of chronic SHIV infection.

Rahman S, Billingsley J, Sharma A, Styles T, Govindaraj S, Shanmugasundaram U JCI Insight. 2022; 7(8).

PMID: 35271506 PMC: 9089783. DOI: 10.1172/jci.insight.155601.


References
1.
Kalams S, Buchbinder S, Rosenberg E, Billingsley J, Colbert D, Jones N . Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection. J Virol. 1999; 73(8):6715-20. PMC: 112756. DOI: 10.1128/JVI.73.8.6715-6720.1999. View

2.
Wherry E, Ahmed R . Memory CD8 T-cell differentiation during viral infection. J Virol. 2004; 78(11):5535-45. PMC: 415833. DOI: 10.1128/JVI.78.11.5535-5545.2004. View

3.
Hanke T, McMichael A, Dennis M, Sharpe S, Powell L, McLoughlin L . Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice. Vaccine. 2005; 23(12):1507-14. DOI: 10.1016/j.vaccine.2004.08.050. View

4.
Greenwald R, Freeman G, Sharpe A . The B7 family revisited. Annu Rev Immunol. 2005; 23:515-48. DOI: 10.1146/annurev.immunol.23.021704.115611. View

5.
Robinson H, Amara R . T cell vaccines for microbial infections. Nat Med. 2005; 11(4 Suppl):S25-32. DOI: 10.1038/nm1212. View